Launch of Latest Innovative Medicines Initiative (IMI) Calls for Proposals
The Innovative Medicines Initiative (IMI) is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Call 18 of the IMI2 programme is open to applications and consists of the following topics:
Central Repository of Digital Pathology Slides to Support the Development of Artificial Intelligence Tools.
Health Outcomes Observatories – Empower Patients with Tools to Measure Their Outcomes in a Standardised Manner Creating Transparency of Health Outcomes.
Improving Patient Access, Understanding and Adherence to Healthcare Information: An Integrated Digital Health Information Project.
Establishing International Standards in the Analysis of Patient Reported Outcomes and Health-related Quality of Life Data in Cancer Clinical Trials.
Accelerating Research & Innovation for Advanced Therapy Medicinal Products.
Supporting the Development of Engineered T Cells.
IMI will contribute €86 million to projects funded under Call 18; these funds come from Horizon 2020. EFPIA companies and IMI Associated Partners will contribute €75 million, mostly as ‘in kind’ contributions.
IMI is also launching Call 19 of IMI2. This is a Restricted Call is to provide additional support to certain existing IMI2 projects to allow them to build on their achievements and maximise the impacts of their work.
The deadline for submitting short proposals (Call 18) or full proposals (Call 19) is 26 September 2019.
More information about this research funding opportunity and the application process is available on the RESEARCHconnect funding information platform. RESEARCHconnect provides up-to-the minute content, insight and analysis on research funding news and policy. To find out more about how RESEARCHconnect can keep you in the know, and subscription fees, contact us today.